This study will test the ability of a medicine (Quetiapine) that is used to treat
schizophrenia or bipolar disorder to reduce the effects of methamphetamine that make it
difficult for users to stop using it. This study will test the ability of a medicine that is
used to treat schizophrenia or bipolar disorder to reduce the effects of methamphetamine
that make it difficult for users to stop using it. The investigator thinks quetiapine will
lessen the effects of methamphetamine.
The specific goal of this project is to examine whether quetiapine will alter the behavioral
effects of methamphetamine without producing major cardiovascular changes or toxic effects
under controlled laboratory conditions. This goal will be accomplished using a
methamphetamine challenge procedure in which quetiapine will be given orally prior to
intravenous (iv) methamphetamine administration. This will allow rapid and systematic
evaluation of the therapeutic potential of this medication.
Results of this drug-interaction study will help determine further investigations of the
clinical efficacy of this and other dopamine-active agents. We hypothesize that quetiapine
will reduce the self-reported, performance and cardiovascular effects of methamphetamine.
1. Must be between the ages of 18-50.
2. Must have experience with IV methamphetamine use, with self-reported recent history
of weekly use being greater than the total administered in the study. Recent use will
be confirmed by a urine toxicology screen positive for amphetamines. We will recruit
moderate to frequent users of methamphetamine. Moderate use is defined as use from
once or twice every six weeks to weekly. Frequent users are defined as individuals
who use greater than weekly.
3. Must have recent use confirmed by a urine toxicology screen positive for
4. Must not be seeking treatment for methamphetamine abuse/dependence.
1. Ill health (major cardiovascular, renal, endocrine, hepatic disorder).
2. Current diagnosis of other drug or alcohol physical dependence (other than nicotine
3. History of major organic psychiatric disorder (psychosis, schizophrenia, bipolar,
mania) or significant psychiatric symptoms at the time of evaluation for study
participation, including suicidal ideation.
4. Pregnancy, plans to become pregnant or fertile women without adequate means of
5. Present or recent use of over-the-counter or prescription psychoactive drug or drugs
that would have major interaction with drugs to be tested.
6. Medical contraindication to or prior serious adverse effects from methamphetamine or
stimulants (i.e., seizures, cardiac arrest) or medical contraindication to test
agents (see risks section). Significant physical or psychiatric illness which might
impair the ability to safely complete the study or that might be complicated by the
study drugs, including prior seizures (after age 8) or other active neurological
disease or clinically significant abnormalities on physical examination or screening
7. Current enrollment in a methamphetamine, alcohol, or other drug treatment program or
current legal problems relating to methamphetamine, alcohol, or other drug use,
including awaiting trial or supervision by a parole or probation officer
8. Body Mass Index >30 or <18
9. Currently trying to quit methamphetamine use or seeking treatment for methamphetamine
10. History of serious adverse event or hypersensitivity to methamphetamine or other
11. Currently taking any medication (including highly active antiretroviral therapy
(HAART) for HIV) other than over-the-counter nonsteroidal anti-inflammatory
medications, topical medications, inhaled asthma therapy, and over-the-counter
12. Use within the last month of the Vicks Nasal Inhaler or medications that are
metabolized to methamphetamine (e.g. selegiline)